Association of UACR and UPCR with kidney failure: analysis of observational data in children with chronic kidney disease Authors: Murunga Sheila, Jonas Hofstetter, Aysun K Bayazit, Ali Duzova, Lukasz Obrycki, Anke Doyon, Justine Bacchetta, Rukshana Shroff, Julia Thumfart, Francesca Lugani, Jerome Harambat, Anette Melk, Uwe Querfeld, Franz Schaefer Published: 2026 ABSTRACT ABSTRACTBackgroundUrinary albumin-to-creatinine ratio (UACR) and protein-to-creatinine ratio (UPCR) are established markers for risk stratification in pediatric chronic kidney disease (CKD), yet their relative strength of association with CKD progression remains unclear. We compared a head-to-head evaluation of UACR and UPCR associations with estimated glomerular filtration rate (eGFR) decline and kidney survival in a large pediatric CKD cohort.MethodsWe analyzed 596 children aged 6–17 years with CKD stages 3–4 from the 4C cohort. Baseline UACR and UPCR were log-transformed and z-standardized. CKD progression was evaluated by annual eGFR slope and a composite kidney outcome (50% eGFR loss, eGFR <10 mL/min/1.73 m² or kidney replacement therapy). Associations per 1-SD increase were estimated using adjusted linear mixed-effect and Cox models. Differences in effect sizes were assessed using bootstrap-based bias-corrected and accelerated 95% confidence intervals (CI).ResultsMean (SD) age was 12.4 (3.3) years; 70% had congenital anomalies of the kidneys and urinary tract (CAKUT). Median (interquartile range) eGFR was 28 (14) mL/min/1.73 m². Over a median follow-up of 2.5 (3.8) years, 334 events occurred. A 1-SD increase in log-UACR and log-UPCR was associated a 2.17-fold (95% CI 1.84 to 2.55) and 1.70-fold (95% CI 1.52 to 1.90) higher risk of the composite outcome, respectively; UACR showed a 28% stronger association (HRUACR/HRUPCR = 1.28; 95% CI 1.12 to 1.53). No relative difference was found in overall eGFR slope change (slope ∆UACR – slope ∆UPCR = –0.05; 95% CI –0.50 to 0.24), but UACR showed stronger associations in children with advanced CKD and severe proteinuria.ConclusionBoth UACR and UPCR were independently associated with CKD progression in this pediatirc cohort. In direct comparison, UACR demonstrated stronger associations with adverse kidney outcomes, suggesting a comparatively greater prognostic signal and supporting current guideline emphasis on albuminuria for risk stratification and intervention outcome monitoring. What was known: Both urinary albumin-to-creatinine ratio (UACR) and protein-to-creatinine ratio (UPCR) are established markers used for chronic kidney disease (CKD) diagnosis and monitoring. Both urinary albumin-to-creatinine ratio (UACR) and protein-to-creatinine ratio (UPCR) are established markers used for chronic kidney disease (CKD) diagnosis and monitoring. However, information based on direct within-cohort comparison of their relative association strength with kidney outcomes is limited in the pediatric CKD population. However, information based on direct within-cohort comparison of their relative association strength with kidney outcomes is limited in the pediatric CKD population. This study adds: Using a large prospective pediatric CKD cohort, this study provides a formal within-sample comparison of the magnitude of associations between UACR and UPCR with kidney outcomes, showing stronger associations for UACR in advanced CKD and severe proteinuria, and similar performance in earlier disease stages. Using a large prospective pediatric CKD cohort, this study provides a formal within-sample comparison of the magnitude of associations between UACR and UPCR with kidney outcomes, showing stronger associations for UACR in advanced CKD and severe proteinuria, and similar performance in earlier disease stages. Potential impact: These findings provide pediatric comparative evidence aligned with KDIGO emphasis on albuminuria, demonstrating stronger associations for UACR compared with UPCR in high-risk groups and suggesting the use of UACR as a potential surrogate endpoint in future pediatric CKD clinical trials. These findings provide pediatric comparative evidence aligned with KDIGO emphasis on albuminuria, demonstrating stronger associations for UACR compared with UPCR in high-risk groups and suggesting the use of UACR as a potential surrogate endpoint in future pediatric CKD clinical trials. INTRODUCTION Pediatric chronic kidney disease (pCKD), a condition that affects 15–75 cases per million children [1], causes cardiovascular, bone, growth and neurocognitive complications [2–4]. The majority of cases result from congenital anomalies of the kidney and urinary tract (CAKUT) and genetic or immune-mediated nephropathies, imposing a lifelong medical and psychosocial burden [5–7]. Reliable biomarkers are essential for early diagnosis and timely interventions to slow disease progression. Kidney disease progression can be assessed as the rate of GFR loss expressed by the linear regression slope or as the time to reaching a clinically relevant loss of kidney function. While both approaches are used as endpoints in clinical trials, urinary protein excretion is increasingly recognized as a bridging biomarker and surrogate endpoint at least in populations with glomerular disease etiologies [8–10]. The 2024 KDIGO guidelines strongly recommend using UACR and UPCR in CKD monitoring, as they may provide complementary diagnostic insights into disease progression [11]. UACR measures albuminuria, a sensitive marker of glomerular filtration barrier dysfunction [12], and is widely utilized for CKD diagnosis, staging and risk stratification [13, 14]. UPCR quantifies total proteinuria, encompassing both albumin and non-albumin protein losses relevant to tubular and CAKUT-related conditions, and is more commonly used in pediatric clinical settings due to its feasibility and low cost [15, 16]. Despite their widespread use, a direct comparative evaluation of UACR versus UPCR for predicting pCKD progression has not been performed to date, leaving uncertainty regarding their relative associations with progression outcomes in pCKD. While adult studies have compared UACR and UPCR and reported either comparable predictive capabilities for renal outcomes [13, 17], or a stronger association for UACR, particularly in high-risk subgroups [e.g. higher proteinuria, lower estimated glomerular filtration rate (eGFR), diabetes or glomerulopathies] [18], these findings cannot be readily extrapolated to children. CKD in childhood differs substantially from adult CKD in underlying etiologies and age-related kidney pathology [19–21], limiting the transferability of these adult findings to children. In this study, we hypothesized that UACR may show stronger associations than UPCR with longitudinal eGFR decline and adverse kidney outcomes in children with CKD, both at the global population level and in subgroups defined by disease etiology and severity. MATERIALS AND METHODS Study population The Cardiovascular Comorbidity in Children with CKD (4C) Study [22] was a multicentre, prospective cohort study in children aged 6–17 years with an eGFR of 10–60 mL/min/1.73 m2, and not on kidney replacement therapy. Participants were enrolled between 2009 and 2011 and followed at 6-monthly visits until 2018 across 55 pediatric nephrology units across 12 European countries [22]. Ethics committee was obtained centrally (Heidelberg University, S-032/2009) and locally, and the study was registered at ClinicalTrials.gov (NCT01046448). Covariate standardization and kidney outcomes UACR and UPCR were measured in mg/g from spot urine samples collected at the baseline visit, log10-transformed and z-standardized to enable direct comparison of their associations with kidney outcomes. Prospective changes in kidney function were assessed (i) by the annualized rate of eGFR change (eGFR slope) and (ii) by time-to event analysis using a composite kidney outcome endpoint defined by a sustained ≥50% eGFR decline, attainment of CKD stage 5, dialysis initiation or pre-emptive kidney transplantation. Only endpoint-free patients at the baseline visit were included for eGFR slope analysis, and time-to event analysis. eGFR was calculated using the Schwartz equation based on height, serum creatinine, cystatin C and blood urea nitrogen [23]. Statistical analysis Baseline characteristics including patient age (years), BMI (as standard deviation score, SDS [24, 25]), eGFR, mean arterial blood pressure (MAP in SDS [26, 27]), and the urinary biomarkers UACR and UPCR were reported as mean (SD) for normally distributed variables or as median [interquartile ranges (IQR)] for variables with non-normal distributions as verified by the D’Agostino–Pearson test. Categorical variables such as sex and kidney diagnosis (CAKUT vs non-CAKUT) were summarized by counts and percentages (%). Covariate-adjusted Cox proportional hazards regression models were fitted separately for UACR and UPCR to estimate the relative change in the hazard of attaining the composite kidney outcome endpoint associated with a 1-SD increase in the log10-transformed baseline value of each biomarker. Changes in mean annualized eGFR decline associated with a 1-SD increase in log10-transformed baseline UACR and UPCR were estimated by the β-coefficients of continuous time interactions with each standardized urinary biomarker in separate, covariate-adjusted linear mixed-effects models (LMM) of longitudinal eGFR. LMM were specified with patient-specific random intercepts, linear random slopes for time and an unstructured residual covariance matrix. Patients’ longitudinal eGFR measurements were included up to the first eGFR measurement on CKD5 before dialysis initiation or pre-emptive transplantation. Analyses were restricted to eGFR measurements recorded during the first 5 years after baseline to reduce the influence of long-term survivors with dense follow-up in later years on mean eGFR slope estimation. Sensitivity analyses based on full follow-up eGFR data are provided in the Supplementary Material. Multivariable Cox regressions and LMM per urinary biomarker predictor were fitted to the overall analysis cohort and to subgroups defined for the following clinically relevant variables at baseline: age in years (< median; ≥ median), sex (male; female), kidney diagnosis (CAKUT; non-CAKUT), UACR (<0.3; 0.3–1; ≥1 g/g), UPCR (<0.5; 0.5–1.5; ≥1.5 g/g), eGFR (<45; ≥45 mL/min/1.73 m²), MAP SDS (<1.2; ≥1.2). The following baseline covariates were included for multivariable effect-adjustment in the Cox regression and LMM models: sex, kidney diagnosis (CAKUT vs non-CAKUT), and age, eGFR, BMI SDS and MAP SDS as continuous measures. Bootstrap-based comparison of urinary biomarker effects To formally compare the association strength of UACR and UPCR at baseline with the risk of reaching the kidney outcome endpoint, we defined the ratio of their covariate-adjusted hazard ratios (HRUACR/HRUPCR) as a comparative metric. Differences in association strength between urinary biomarkers were assessed by constructing bias-corrected and accelerated (BCa) 95% confidence intervals (CIs) on the empirical bootstrap distribution of this ratio [28]. The bootstrap distribution was obtained by refitting the multivariable Cox regression models for the composite endpoint risk associated with UACR or UPCR on each of 3000 random, patient-wise, event-stratified (outcome event vs censored) resamples of original size and drawn with replacement. This nonparametric bootstrap approach accounts for the within-sample dependence between HRUACR and HRUPCR, as both are estimated on the same individuals, and circumvents the need for an analytical variance expression of their ratio. The null hypothesis of equal composite endpoint association between UACR and UPCR was rejected when the 95% BCa CI of HRUACR/HRUPCR excluded 1. To formally compare the strength of eGFR slope moderation by baseline UACR versus baseline UPCR, we defined the subtraction term of the respective slope moderation effects (∆eGFR_slopeUACR – ∆eGFR_slopeUPCR; henceforth referred to as slope∆UACR – slope∆UPCR) as a comparative metric. Bias-corrected and accelerated (BCa) 95% confidence intervals (CIs) for this comparative metric were derived from the empirical bootstrap distribution obtained by refitting the multivariable LMM for mean eGFR slope moderation by UACR or by UPCR on each of 3000 patient-wise, outcome-stratified (event vs censored) resamples of original size and drawn with replacement. Patient-wise resampling ensured that all repeated measurements of a selected individual were retained in each bootstrap dataset, thereby preserving the longitudinal and nested correlation structure. The null hypothesis of equal eGFR slope moderation by UACR and UPCR was rejected when the 95% BCa CI of slope∆UACR – slope∆UACR excluded 0. All analyses were conducted on complete-case data using R Studio on R version 4.5.0 [29, 30]. The R packages nlme [31], survival [32] and boot [33] were used for multivariable linear mixed-effects modeling, multivariable Cox regression analysis, and for the creation and implementation of a customized bootstrapping algorithm, respectively. RESULTS Patient characteristics We analyzed 596 children with CKD who had UACR and UPCR measurements and complete predictor information available at baseline. The characteristics of the cohort at time of enrolment are given in Table 1. During a median follow-up time of 2.5 (IQR 3.8) years, 334 kidney outcome composite endpoints were observed (14.1% sustained 50% eGFR loss, 45.5% attainment of CKD5, 21.6% dialysis initiation, 18.8% pre-emptive transplantation). A total of 3205 eGFR measurements were available within the first 5 years of observation, corresponding to a median of 5 (3–8) datapoints per patient. Table 1:Baseline characteristics.Total N596Age (years), mean (SD)12.4 (3.29)Female gender204 (34.2)Underlying diagnosisCAKUT417 (70.0)Non-CAKUT179 (30.0)BMI SDS0.20 (1.51)<1.65531 (89.1%)≥1.6565 (10.9%)MAP SDS–0.75 (2.03)<1.2504 (84.6%)≥1.292 (15.4%)eGFR (mL/min/1.73 m2)28 (14)≥4554 (9.1%)<45542 (90.9%)UACR, g/g0.33 (1.05)< 0.3292 (49.0%)0.3–1.0134 (22.5%)>1.0170 (28.5%)UPCR, g/g1.23 (2.28)<0.5135 (22.7%)0.5–1.5195 (32.7%)>1.5266 (44.6%)Data are given as median (IQR) or n (%) unless indicated otherwise. Baseline characteristics. Data are given as median (IQR) or n (%) unless indicated otherwise. Distribution of baseline UACR and UPCR The baseline UACR and UPCR values showed right-skewed distributions. After log10-transformation, both urinary biomarkers approximated a normal distribution. However, the log10-transformed UACR values showed greater variability compared with log10-transformed UPCR (SD 0.88 vs 0.52), and their mean values also differed. Z-standardization of the log10-transformed values yielded close alignment of the UACR and UPCR distributions, allowing direct comparison of prognostic associations with kidney outcome (Fig. 1). Standardization of baseline UACR and UPCR to compare their associations with clinical outcomes. Gaussian kernel density estimation with Silverman’s rule-of-thumb bandwidth selection was used to visualize the distributional density of each urinary biomarker. Comparison of baseline UACR and UPCR in predicting eGFR decline In the multivariable linear mixed-effects models, both UACR and UPCR were significantly associated with greater eGFR decline (Fig. 2). In the overall cohort, the change in annual mean eGFR slope was –0.97 (95% CI –1.22 to –0.72) per 1-SD increase in log10-UACR and –0.92 (95% CI –1.18 to –0.66) per 1-SD increase in log10-UPCR. In the overall cohort, the subtraction term of mean eGFR slope moderation coefficients (slope∆UACR – slope∆UPCR) was –0.05 (95% CI –0.50 to 0.24), indicating no significant difference between the two urinary biomarkers’ association with change in annual mean eGFR slope. Associations of standardized baseline UACR and UPCR with change in eGFR slope and comparison of associations. Forest plots in left and middle panels denote covariate-adjusted estimates of mean annual eGFR slope moderation per 1-unit increase in standardized UACR or UPCR, with horizontal lines and numbers in parentheses indicating 95% CI, respectively. In the right panel, the dots and numbers indicate the subtraction term of the UACR- and UPCR-related mean eGFR slope moderation effects, with horizontal lines and numbers in parentheses indicating the bias-corrected and accelerated 95% CI as obtained from bootstrapping. The dashed vertical lines show where eGFR slope moderation effects would indicate no change in mean annual eGFR slope by a 1-unit increase in standardized UACR or UPCR (left and middle panels), or where the subtraction term of UACR- and UPCR-related eGFR slope moderation effects would indicate equal association with magnitude and direction of change in mean eGFR slope between UACR and UPCR (right panel). In subgroup analyses both urinary biomarkers showed consistent, independent associations with greater eGFR decline across groups defined by sex, kidney diagnosis, age, eGFR, proteinuria and blood pressure at baseline (Fig. 2). Notably, stronger associations with eGFR slope were observed for UACR compared with UPCR in older children (slope∆UACR – slope∆UPCR = –0.38, 95% CI –0.78 to –0.11), in boys (slope∆UACR – slope∆UPCR = –0.36, 95% CI –0.69 to –0.15), in children with moderate (UACR 0.5–1 g/g; slope∆UACR – slope∆UPCR = –4.24, 95% CI –8.31 to –1.58) and severe (UACR ≥1 g/g; slope∆UACR – slope∆UPCR = –3.32, 95% CI –7.24 to –0.38) albuminuria, with severe proteinuria (UPCR ≥1.5 g/g; slope∆UACR – slope∆UPCR = –1.66, 95% CI –3.26 to –0.76) and in those with eGFR <45 mL/min/1.73 m2 (slope∆UACR – slope∆UPCR = –0.40, 95% CI –0.66 to –0.18) (Fig. 2). Comparison of baseline UACR and UPCR in predicting kidney outcome In the multivariable Cox regression analysis, both baseline UACR and UPCR were significantly associated with the risk of reaching the composite endpoint. In the overall cohort, the hazard ratio (HR) was 2.17 (95% CI 1.84 to 2.55) per 1-SD increase in log10-UACR, and 1.70 (95% CI 1.52 to 1.90) per 1-SD increase in log10-UPCR. The ratio of HRs (HRUACR/HRUPCR) was 1.28 (95% CI 1.12 to 1.53), indicating that UACR provided a 28% stronger association with the risk of reaching the endpoint than UPCR. The relative effects of both biomarkers on endpoint-free survival are visualized in Fig. 3. Time to composite endpoint in pCKD patients stratified according to baseline proteinuria (left panel) or albuminuria (right panel). Blue, green and red curves represent effect of 1-unit differences in standardized UPCR and UACR levels. Curves are shown for boys with CAKUT diagnosis and median baseline values for eGFR, MAP SDS, BMI SDS and age. Shaded areas represent 95% CIs. Forest plots in left and middle panel indicate covariate-adjusted HRs for a 1-unit increase in standardized UACR or UPCR, with horizontal lines and numbers in parentheses indicating the 95% CIs, respectively. In the right plot panel, the dots and numbers indicate the ratios of the UACR- and UPCR-related HRs, with horizontal lines and numbers in parentheses indicating the bias-corrected and accelerated 95% CIs as obtained from bootstrapping. The dashed vertical lines show where HRs would indicate no change in risk of adverse kidney outcome by a 1-unit increase in standardized UACR or UPCR (left and middle panel), or where the ratio of UACR- and UPCR-related hazard ratios would indicate equal strength of positive association with risk of adverse kidney outcome between UACR and UPCR (right panel). Subgroup analysis showed that both urinary biomarkers showed consistent positive associations with progression endpoint risk across categories of baseline age, sex, kidney diagnosis, baseline eGFR and MAP SDS (Fig. 4). Notably, baseline UACR demonstrated a stronger association with endpoint risk compared with baseline UPCR in younger children (HRUACR/HRUPCR = 1.23, 95% CI 1.06 to 1.45) as well as older children (HRUACR/HRUPCR = 1.44, 95% CI 1.09 to 2.00), in boys (HRUACR/HRUPCR = 1.32, 95% CI 1.12 to 1.66), in patients with severely elevated baseline proteinuria (UPCR ≥1.5 g/g; HRUACR/HRUPCR = 1.89, 95% CI 1.25 to 3.34) and albuminuria (UACR ≥1 g/g; HRUACR/HRUPCR = 2.45, 95% CI 1.10 to 6.06), in patients with CAKUT diagnosis (HRUACR/HRUPCR = 1.43, 95% CI 1.19 to 1.93), in patients with baseline eGFR <45 mL/min/1.73 m2 (HRUACR/HRUPCR = 1.33, 95% CI 1.15 to 1.59) and in patients with <1.2 baseline MAP SDS (HRUACR/HRUPCR = 1.29, 95% CI 1.12 to 1.59). Association of standardized baseline UACR and UPCR with composite kidney endpoints, and comparison of associations. Forest plots in left and middle panel indicate covariate-adjusted hazard ratios for a 1-unit increase in standardized UACR or UPCR, with horizontal lines and numbers in parentheses indicating the 95% confidence intervals (CI), respectively. In the right plot panel, the dots and numbers indicate the ratios of the UACR- and UPCR-related hazard ratios, with horizontal lines and numbers in parentheses indicating the bias-corrected and accelerated 95% CI as obtained from bootstrapping. The dashed vertical lines show where hazard ratios would indicate no change in risk of adverse kidney outcome by a 1-unit increase in standardized UACR or UPCR (left and middle panel), or where the ratio of UACR- and UPCR-related hazard ratios would indicate equal strength of positive association with risk of adverse kidney outcome between UACR and UPCR (right panel). DISCUSSION We hypothesized that UACR is more strongly associated than UPCR with adverse kidney outcomes in children with CKD. Performed within the framework of the large European multicenter 4C cohort, this analysis provides a direct within-cohort, head-to-head comparison of the strength of association between UACR and UPCR and clinically relevant kidney outcomes in pCKD. Our findings indicate that baseline UACR shows comparatively stronger and more consistent associations with adverse kidney outcomes than UPCR in this population. While both UPCR and UACR were independently associated with eGFR decline and the risk of progressing to the composite endpoint, UACR globally had a 28% greater association with adverse kidney outcome risk than UPCR. With respect to eGFR slope moderation the two biomarkers showed broadly comparable associations in the overall cohort, whereas subgroup analyses suggested that UACR was more closely associated with eGFR decline than UPCR in children with advanced CKD and moderate to severe albuminuria. These patterns may indicate that albuminuria captures aspects of disease severity or glomerular injury that are particularly relevant in later stages of CKD. From a biological perspective, several non–mutually exclusive mechanisms may explain the comparatively stronger associations observed for UACR. Given that our cohort was predominantly composed of CAKUT patients, our findings may reflect predominantly low-molecular proteinuria due to tubular dysfunction in early CKD and a gradually increasing proportion of albuminuria due to secondary glomerular injury as CKD advances and reduced nephron endowment leading to maladaptive hyperfiltration, elevated intraglomerular pressure and podocyte strain [26]. On the other hand, the non-albumin protein fraction is highly variable in children with CKD and a distinct shift from “tubular” to “albumin-predominant” proteinuria in non-glomerular disorders has not been established [10, 34]. Therefore, we interpret the stronger associations of UACR primarily as reflecting a comparatively tighter relationship with disease severity rather than a specific temporal change in pathogenesis. Moreover, albumin-specific assays are generally better standardized and more sensitive compared with total protein measurements, which may have influenced the observed association strengths [11]. Previous pediatric studies have shown that both UACR and UPCR are associated with CKD progression [10, 35]. However, direct quantitative comparisons of the relative magnitude of these associations within the same pediatric cohort have been limited. In the CKD in Children (CKiD) cohort, UACR, UPCR and non-albumin PCR showed similar associations with kidney function decline, a pattern consistent with our findings where both biomarkers showed comparable associations with CKD progression in children [10]. However, CKiD predominantly included children with mild-moderate CKD and lacked a formal comparison of effect sizes. Consequently, pediatric reviews have questioned whether UACR provides incremental associative value in children with structural kidney disease, where tubular proteinuria may predominate early [15]. By examining a large, higher-risk cohort with advanced CKD and long-term outcome follow-up, the present analysis extends these observations by directly comparing association strengths, suggesting that UACR may offer comparatively greater prognostic discrimination particularly in children with more advanced disease or higher levels of proteinuria. This study benefits from its prospective, multicentre design, centralized biomarker measurement and a large representation of advanced CKD and CAKUT, addressing the underrepresentation of high-risk children in previous studies. A major strength is the direct head-to-head of effect sizes between UACR and UPCR using Cox and mixed-effects models with bootstrap BCa CIs and stratified subgroup analysis, providing clinically meaningful insight into context-specific biomarker associations with CKD progression, and enabling estimation of their relative prognostic signal within the same individuals. Several limitations should be recognized. First, the cohort was dominated by children with advanced CKD and a high prevalence of CAKUT. While representative of pCKD epidemiology, this etiological composition may influence the relative performance of UACR and UPCR. Structural and tubulointerstitial disorders often exhibit lower albumin fractions compared with primary glomerular diseases, and therefore the comparative advantage of UACR observed here may not be directly generalizable to populations with predominantly glomerular or nephrotic-range proteinuria. Moreover, spot urine samples are susceptible to orthostatic and diurnal variation, although they are more readily applied in daily clinical practice than timed samples. Residual confounding remains possible due to the inherent biological and measurement variability of urinary markers, and reliance on baseline measurements precludes assessing how longitudinal changes in UACR or UPCR may influence prognostic accuracy. Finally, because our analyses focus on baseline measurements, we cannot determine whether longitudinal trajectories or repeated measurements of either biomarker would provide additional prognostic information. In summary, both UACR and UPCR were independently associated with CKD progression, with UACR demonstrating comparatively stronger associations with adverse outcomes within this pediatric cohort. From a clinical perspective, these findings support prioritizing albuminuria measurements for risk stratification when feasible, while recognizing that both markers retain clinical utility. UACR may also be preferred over UPCR as a surrogate endpoint for clinical trials in the pCKD population. Nevertheless, UPCR remains a pragmatic alternative where albumin-specific assays are unavailable or costly, especially in resource-limited settings. Further interventional research is needed to establish whether lowering UACR leads to better long-term pCKD outcomes, and to monitor whether tracking repeated measurements or biomarker trending offer more accurate prognostic information than relying on a single measurement. Supplementary Material